BMRN: BioMarin Pharmaceutical Inc. is a Buy

The current rating for BMRN is 56, which is 12% above its historic median rating of 50. This indicates lower risk than normal.

The rating is currently showing a higher than normal reading, suggesting risk levels could be lower than normal.